Opioid use disorder is a growing public health crisis. An estimated 24.6 million Americans use illicit drugs \[[@CIT0001]\]. Rates of morbidity and mortality from illicit drug use are increasing, with deaths from opioid use nearly quadrupling over the previous 2 decades \[[@CIT0002], [@CIT0003]\]. Infection is a significant cause of morbidity and mortality in people who inject drugs (PWID). Inpatient admissions for infections associated with injection drug use (IDU) may be twice as expensive as other admissions in PWID \[[@CIT0004]\]. Skin and soft tissue infections are most common in PWID \[[@CIT0005], [@CIT0006]\], but bacteremia, endocarditis, osteomyelitis, and septic arthritis also occur. These infections are typically treated with prolonged intravenous (IV) antibiotic courses \[[@CIT0007], [@CIT0008]\]. However long-term parenteral access raises concerns about use of the line for recreational purposes, which may pose additional risks to the patient \[[@CIT0009]\].

Outpatient parenteral antimicrobial therapy (OPAT) programs are increasingly relied upon to facilitate completion of IV antimicrobial treatment courses after hospital discharge \[[@CIT0010], [@CIT0011]\]. Outpatient parenteral antimicrobial therapy has been effective in the management of several infectious diseases including endocarditis, soft tissue infections, bacteremia, and bone and joint infections \[[@CIT0012]\]. Guidelines for the safe administration of OPAT use have been developed. Important features that enable safe OPAT delivery include oversight by an infectious diseases physician, a safe home environment, and reliable communication between patient and caregivers \[[@CIT0016]\]. Research on OPAT has focused predominantly on the non-PWID population \[[@CIT0017]\], and little is known about the use of home OPAT among PWID. The option of completing IV therapy at home is often deemed unsafe in the setting of recent drug use. Alternative solutions are often favored; these include prolonged inpatient admissions, completion of therapy at a skilled nursing or rehabilitation facility (SNF/rehab), and oral antimicrobials. However, these options may cost more and/or may risk diminished efficacy \[[@CIT0018]\]. There is an urgent need to better understand the risks of outpatient parenteral antimicrobials in PWID. In this study, we describe the outcomes of PWID discharged from a single academic medical center either to home or to a SNF/rehab with OPAT management.

METHODS {#s5}
=======

This was a retrospective observational study to assess the safety and outcomes of PWID receiving IV antimicrobial therapy discharged to either home or SNF/rehab. The study was conducted at Massachusetts General Hospital (MGH), which serves both a primary care and tertiary referral population in Boston, Massachusetts. We used the Research Patient Data Registry (RPDR), a centralized clinical database for hospitals in the Partners Healthcare system, to identify patients admitted to MGH between January 1, 2010 and December 31, 2015 with diagnoses of endocarditis, prosthetic joint infection, septic arthritis, and osteomyelitis and a concurrent diagnosis of substance use disorder, including but not limited to those having an opioid use disorder. Within this list, we identified those patients who were also followed by the MGH OPAT program, which enrolls patients who require 2 or more weeks of IV antibiotic therapy after discharge. Diagnosis codes and chart review were used to confirm inclusion of PWID with known or suspected IV drug use in the preceding 2 years. We defined recent IDU as known or suspected IDU (IV, intramuscular, or skin popping) in the 1--24 months preceding admission and ongoing IDU as occurring within the month preceding admission.

Patients discharged to SNF/rehab were included if they were enrolled in the OPAT program for antibiotic monitoring and expected to return to MGH for outpatient follow-up. The majority of patients discharged to state-supported rehabilitation facilities, which includes many patients with IDU, are followed by Infectious Diseases physicians at these facilities and were excluded. Patients who used outpatient infusion centers for antibiotic administration were also excluded.

Data were obtained from the RPDR, electronic medical records (EMR), and OPAT database. The information we collected included demographics of ethnicity, age, and sex, index hospitalization, infectious disease diagnosis, and planned antibiotic course. Details on the substance use history and on planned addictions treatment and monitoring after discharge were abstracted from the EMR. When available, information about safe discharge plan counseling and family involvement in the substance use disorder plan was also included. Extracted outcome data included duration of antimicrobial therapy, line complications (infection, thrombosis), IDU relapse, readmission, loss to follow-up, and death. The MGH OPAT database was used to identify rates of line infections, readmission, and death among all patients enrolled in the MGH OPAT program during part of the same time period (2013--2015) for comparison.

Descriptive statistics of central tendency were used to analyze patient data. The characteristics and outcomes of patients discharged home versus to a facility were compared using 2-sided Fisher's exact tests. The small size of the study population did not permit multivariable modeling. The Partners Institutional Review Board reviewed the study protocol and granted a waiver for informed consent.

RESULTS {#s6}
=======

Searches of the RPDR and OPAT database identified 170 hospitalized patients with concurrent infectious disease and substance use disorder diagnoses who were enrolled in the MGH OPAT program after discharge. Of these 170 patients, 52 met inclusion criteria: 21 were discharged home and 31 were discharged to SNF/rehab. Of the 118 patients excluded, the majority (109, 92%) could not be confirmed as having known or suspected IDU in the 24 months preceding admission. Seven (6%) patients were discharged without an IV line, and 3 (2%) patients had OPAT courses that were outside of our study period; these were also excluded.

Of the 21 patients discharged home, 18 (86%) patients had a history of opioid IDU, 2 (9%) had a history of both opioid and cocaine IDU, and 1 (5%) patient had a history of cocaine IDU ([Table 1](#T1){ref-type="table"}). Cocaine use history was more common among those discharged to SNF/rehab (14, 45%). Patients discharged to SNF/rehab had a higher rate of ongoing IDU than of those discharged home (68% vs 33%, *P* \< .05). Among all patients, the 2 most common diagnoses were osteomyelitis (36%) and endocarditis (25%). Methicillin-sensitive *Staphylococcus aureus* (MSSA) was the most common organism isolated (54%), followed by methicillin-resistant *S aureus* (17%). The most common IV antibiotics administered after discharge were cephalosporins (46%) and penicillins (37%).

###### 

Characteristics of Patients Discharged to Home and Rehabilitation

  Complications                 Discharged to Home (n = 21)   Discharged to Rehab (n = 31)   *P* Value (Fisher\'s Exact Test )
  ----------------------------- ----------------------------- ------------------------------ -----------------------------------
  Demographics                                                                               
  Gender                                                                                     
   Female                       6 (29%)                       10 (32%)                       
   Male                         15 (71%)                      21 (68%)                       
  Ethnicity                                                                                  
   Black                        1 (5%)                        0                              
   Hispanic                     0                             0                              
   Asian                        0                             0                              
   White                        20 (95%)                      30 (97%)                       
   Other/Unknown                0                             1 (3%)                         
   Age (Median, Range)          30 (23--51)                   33 (24--61)                    
  Injection Drug History                                                                     
   Ongoing                      7 (33%)                       21 (68%)                       .01
   Within 24 months             14 (67%)                      10 (32%)                       
   Opioids                      20 (95%)                      28 (90%)                       
   Cocaine                      3 (14%)                       14 (45%)                       
  Admission Information                                                                      
  Diagnosis                                                                                  
   Endocarditis                 8 (38%)                       6 (19%)                        
   Osteomyelitis                6 (29%)                       13 (42%)                       
   Prosthetic Joint Infection   1 (5%)                        1 (3%)                         
   Septic Arthritis             5 (24%)                       10 (32%)                       
   Other                        3 (14%)                       14 (45%)                       
  Pathogen                                                                                   
   MRSA                         3 (14%)                       6 (19%)                        
   MSSA                         12 (57%)                      16 (52%)                       
   Other Gram positive          6 (29%)                       8 (26%)                        
   Other Gram negative          2 (10%)                       4 (13%)                        
   Fungal                       1 (5%)                        0                              
  Treatment                                                                                  
   Penicillins                  11 (52%)                      8 (26%)                        
   Vancomycin                   3 (14%)                       7 (23%)                        
   Cephalosporins               7 (33%)                       17 (55%)                       
   Daptomycin                   3 (14%)                       3 (10%)                        
   Fluoroquinolones             0                             1 (3%)                         
   Carbapenems                  0                             1 (3%)                         
  Substance Abuse Treatment     12 (57%)                      5 (16%)                        \<.05
   Medication                   9 (43%)                       5 (16%)                        .06
   Counseling                   9 (43%)                       3 (10%)                        .01
   Toxicology Monitoring        5 (24%)                       2 (6%)                         .10
   IV risk counseling           20 (95%)                      13 (42%)                       \<.01
   Family involvement           8 (38%)                       5 (16%)                        .11

Abbreviations: IV, intravenous; MRSA, methicillin-resistant *staph aureus*; MSSA, methicillin-susceptible *staph aureus*.

Documentation of discharge planning was reviewed for addictions medication treatment and monitoring after discharge, inclusion of family members in discharge planning, and safety counseling ([Table 1](#T1){ref-type="table"}). Patients discharged to home had more documented substance use disorder discharge planning than those discharged to SNF/rehab. Twelve (57%) PWID discharged home versus 5 (16%) discharged to SNF/rehab received any substance use disorder treatment (*P* \< .05). Most patients (20, 95%) discharged home received counseling on the risks of discharge with an IV catheter, compared with 13 (42%) of those discharged to SNF/rehab (*P* \< .05). Family members were more commonly involved in discharge plans for PWID discharged home (8, 38%) than for those discharged to SNF/rehab (5, 16%), although this was not statistically significant. Five (24%) patients discharged to home versus 2 (6%) patients discharged to SNF/rehab had routine toxicology monitoring while on OPAT (*P* \> .05).

Complications of OPAT therapy included line infections, relapse of IDU, loss to follow-up, readmission, and death ([Table 2](#T2){ref-type="table"}). Overall complications were not more likely among PWID discharged to home compared with those at SNF/rehab (4 \[19%\] vs 11 \[35%\], *P* \> .05). There were also no differences in rates of individual complications between the 2 groups. One (5%) patient discharged to home had a line infection compared with 5 (16%) discharged to a rehabilitation facility. One (5%) patient discharged to home had documented relapse of IDU compared with 5 (16%) patients at SNF/rehab. Loss to follow-up occurred in 1 (5%) patient discharged to home and 4 (13%) patients discharged to SNF/rehab. Readmission rates were also similar among patients discharged to home (3, 14%) and to SNF/rehab (9, 29%). For reference, in the overall MGH OPAT population not stratified by drug use, 1.4% of patients (33 of 2096) suffered a line infection, 24 percent (540 of 2214) were readmitted during their treatment course, and 2 percent (44 of 2215) of patients died during their OPAT course.

###### 

Outcomes of Patients Discharged to Home Versus Rehabilitation

  Patient, Diagnosis, and Treatment Factors   Discharged to Home (n = 21)   Discharged to Rehab (n = 31)   *P* Value (Fisher's Exact Test)
  ------------------------------------------- ----------------------------- ------------------------------ ---------------------------------
  Any Complication                            4                             11                             .23
  Line Complications                          1                             5                              .38
  Injection Drug Use Relapse                  1                             5                              .38
  Loss to Follow-up                           1                             4                              .64
  Readmission                                 3                             9                              .72
  Death                                       1                             0                              .40

Seventeen (81%) patients discharged home completed the planned OPAT course and had no known complications from IDU ([Supplementary Table 1](#sup1){ref-type="supplementary-material"}). We were particularly interested in the circumstances of those 4 (19%) patients discharged to home who had complications. One patient being treated for MSSA endocarditis developed a line infection, which was attributed to documented injection drug relapse; he completed his treatment with oral therapy. The second patient was being treated for pseudomonal vertebral osteomyelitis and was lost to follow-up at the end of his treatment course; unsuccessful attempts were made through law enforcement to find the patient to remove the peripherally inserted central catheter. The third patient passed away from cardiac arrest thought to be due to thromboembolic disease from bacterial endocarditis; he had a negative toxicology screen and injection drug relapse was not suspected. A fourth patient required readmission to complete parenteral antibiotics due to unanticipated homelessness. Complications among patients discharged to SNF/rehab are detailed in [Supplementary Table 2](#sup1){ref-type="supplementary-material"}.

DISCUSSION {#s7}
==========

This retrospective review provides an important clinical experience of a cohort of PWID discharged from the hospital on OPAT. Given the worsening IDU and opioid crisis \[[@CIT0019]\], PWID represent a growing proportion of patients requiring long-term parenteral antibiotics for increasingly complex infections \[[@CIT0007]\]. In this cohort of patients discharged to home or to SNF/rehab, a majority were able to safely complete their OPAT courses. The group of patients discharged home on OPAT did not have a significantly higher rate of complications, including rates of injection drug relapse, readmission, line complication, and follow-up, compared with those who were discharged to a rehabilitation facility. For carefully selected patients, discharge to home may be a safe and lower cost alternative to prolonged inpatient admissions or SNF/rehab stays, which carry their own risks. Acknowledging these groups were not identical at baseline, and future randomized studies should optimally be done to better compare outcomes.

Addressing the opioid crisis itself is crucial to controlling the rate of infections resulting from IDU. The route and practice of injection, such as skin popping and unclean needle use, are contributing to the incidence of infections and are being addressed through harm reduction strategies including education and safe needle exchanges \[[@CIT0020], [@CIT0021]\]. Integration of addictions care in the treatment of PWID with infections is equally important in reducing complications. In one study, patients being treated for endocarditis associated with IDU were found to have low rates of addiction counseling or treatment \[[@CIT0022]\]. Although more patients discharged to rehabilitation in our study had ongoing IDU at the time of admission, fewer of these patients were receiving substance use disorder treatment at the time of discharge (addictions counseling and/or medication), which may also increase the risk of OPAT complication.

Several guidelines have been proposed for identifying patients in general who are safe candidates for OPAT, but none have been developed that specifically address PWID. Available guidelines recommend that OPAT candidates for discharge home be medically stable, understand the OPAT plan, and have access to transportation and systems for smooth communication; patients with substance use disorder are generally not believed to be suitable candidates for home OPAT \[[@CIT0023], [@CIT0024]\]. In our study, carefully selected patients were able to complete their OPAT course at home. Characteristics in our study that were associated with adverse OPAT outcomes included lack of family involved in discharge planning, which is similar to what is seen in non-PWID settings \[[@CIT0013]\]. Time since last IDU may also be a factor in complication risk; more patients selected for home discharge in this study had not used within the month before their admission.

Increased time since last IVDU was also associated with a decreased risk of complications for PWID in OPAT in another study \[[@CIT0025]\]. Based on our experience and other published studies, we propose additional considerations for safe OPAT discharge for PWID: these include patient engagement in addiction care including strong consideration for initiation of pharmacotherapy \[[@CIT0026], [@CIT0027]\], a reliable patient support network including family and/or friends who understand the treatment plan and are aware of the patient's substance use disorder, consultation with outpatient addiction providers if applicable, and prior evidence of abstinence from IDU. The patient should also be vested in the decision; the patient should be counseled about the risks associated with indwelling IV access, acknowledge those risks, and agree with the decision for OPAT discharge. In some settings, tamper-proof access devices may also be considered. Among highly selected PWID receiving OPAT in Singapore, tamper-proof seals were used for patients who received daily infusions at an infusion center, and we found similar rates of successful completion of OPAT in our cohort \[[@CIT0028]\].

Our study had several important limitations. First, the small sample size limited our ability to perform statistical analyses. Furthermore, many PWID in need of IV antimicrobial therapy after discharge were not able to be included in the study because they were either treated with oral therapy, completed IV antibiotics as an inpatient, or were discharged to SNF/rehab with internal OPAT oversight and were not monitored by the MGH OPAT program. Although we compared patients discharged to home with those discharged to a rehabilitation facility, it is important to note that these were not matched cohorts and were not equivalent at baseline. Patients who were perceived to be higher risk for injection drug relapse or medication nonadherence would have been more likely to be discharged to a SNF/rehab than to home. In addition, patients with more severe or complex infections and significant comorbidities may also have been more likely to have been discharged to SNF/rehab. As such, direct comparisons between the 2 groups are not necessarily valid. More data and/or prospective studies are needed to evaluate the safety and efficacy of OPAT for PWID as well as the utility of specific interventions before discharge.

CONCLUSIONS {#s8}
===========

In conclusion, amidst the growing opioid and IDU epidemic, outpatient treatment options for long-term antibiotic therapy are desperately needed. This retrospective study of a single large tertiary hospital shows that the majority of PWID needing long-term antibiotics and deemed safe for discharge from the hospital to home or to SNF/rehab for OPAT by their primary medical team were able to safely complete their parenteral antibiotic course. Discharge planning that includes counseling and treatment for substance use disorder and involves family members may increase success. Further studies are needed to develop a screening tool to identify PWID who can safely be sent home on OPAT.

Supplementary Data {#s9}
==================

Supplementary materials are available at *Open Forum Infectious Diseases* online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.

###### 

Click here for additional data file.
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